DCM
ATOS icon

Dupont Capital Management’s Atossa Therapeutics ATOS Stock Holding History

Dupont Capital Management’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,343
Closed -$222K – 1719
2021
Q2 		$222K Buy
+2,343
New +$124K 0.01% 1290

Other funds holding ATOS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Dupont Capital Management's ATOS Position: Q3 2021 in Review

Dupont Capital Management sold out of Atossa Therapeutics (ATOS) in Q3 2021, closing a stake of 2,343 shares — an estimated $222K sold.

Dupont Capital Management first reported a position in ATOS in Q2 2021 and held it in 1 quarter. The position peaked at $222K in Q2 2021. 93 funds tracked by Wall St. Rank hold ATOS as of Q3 2021.

  • Dupont Capital Management reported no remaining Atossa Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Dupont Capital Management sold 2,343 Atossa Therapeutics shares in Q3 2021, an estimated $222K.
  • Dupont Capital Management first reported a position in Atossa Therapeutics in Q2 2021 and held it in 1 quarter.
  • Dupont Capital Management's Atossa Therapeutics position peaked at $222K in Q2 2021.
  • 93 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q3 2021.

Based on Dupont Capital Management's 13F filing for Q3 2021, filed 3 Nov 2021.